We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Must Find a Better Way to Adhere to Precedent Tradition When Evaluating New Drugs, Say Researchers
FDA Must Find a Better Way to Adhere to Precedent Tradition When Evaluating New Drugs, Say Researchers
The FDA’s drug approval decisions are made in a siloed, ad hoc manner, rather than using institutional knowledge of similar decisions that went before at the agency. And often, the judgments FDA officials make about the research before them on drug candidates are too subjective.